A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors

NCT05961111 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Sarcoma
Carcinoma
Digestive Cancer
Breast Cancer
Lung Cancer
Brain Cancer
Melanoma
Gynecologic Cancer
Head and Neck Cancer
Kidney Cancer

Interventions

DRUG: Recombinant oncolytic herpes simplex virus type 1 (R130)

Sponsor

Shanghai Yunying Medical Technology

Collaborators

[object Object]